Form 4: Director Bill Maher Increases Stake in abrdn Life Sciences Investors
SEC Form 4 Filing
Bill Maher, a director of abrdn Life Sciences Investors, recently acquired 650 shares of common stock through an indirect purchase by spouse.
Summary
- On August 23, 2024, Bill Maher, a director of abrdn Life Sciences Investors, indirectly acquired 650 shares of common stock.
- The purchase was made at a price of $15.37 per share.
- Following the transaction, Maher's beneficial ownership includes 1,715.2134 shares held indirectly through a spouse.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Positives
- The director's purchase could be interpreted as a positive signal about their confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their trading activities.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/23/2024 | Date of transaction: Bill Maher acquired 650 shares of common stock. |
| 08/27/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.